BRCA1 and ovarian carcinoma: However, our results support the use of olaparib as maintenance therapy for PSR ovarian cancer patients with a BRCA1/2 mutation as olaparib is not only highly effective but also has strong potential to become a cost-effective treatment option when the cost is reduced by 60% in China.